Septerna (NASDAQ:SEPN) Shares Gap Down – What’s Next?

Posted by Joseph Casey on Jan 8th, 2025

Septerna, Inc. (NASDAQ:SEPN – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $23.69, but opened at $22.88. Septerna shares last traded at $23.43, with a volume of 2,627 shares.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on SEPN shares. Cantor Fitzgerald began coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price target on the stock. TD Cowen began coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a “buy” rating for the company. JPMorgan Chase & Co. started coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target on the stock. Finally, Wells Fargo & Company assumed coverage on Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective for the company.

Check Out Our Latest Report on Septerna

Septerna Trading Up 1.9 %

The business has a 50-day moving average price of $23.73.

Insider Activity at Septerna

In related news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of Septerna stock in a transaction on Monday, October 28th. The stock was acquired at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the acquisition, the insider now directly owns 6,215,591 shares of the company’s stock, valued at $111,880,638. This represents a 6.34 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Septerna Company Profile

(Get Free Report)

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.